ISPC iSpecimen Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.0%
TTM net income YoY5.9%
TTM EPS YoY180.8%
Revenue 3-yr CAGR-61.2%
Net income 3-yr CAGR—
Margins
Gross margin-10.3%
Operating margin-1,455.3%
Net margin-1,797.3%
FCF margin—
EBITDA margin-1,364.6%
Returns
ROE-303.9%
ROA-116.1%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets58.1%
Debt / equity0.00x
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $244,034 | $151,940 | $156,009 | $51,761 | $106,592 | $713,135 | $1.06M | $1.48M |
| Cost of revenue | $91,156 | $83,290 | $84,410 | $407,284 | $204,593 | $444,177 | $657,279 | $1.28M |
| Gross profit | $152,878 | $68,650 | $71,599 | -$355,523 | -$98,001 | $268,958 | $400,231 | $199,241 |
| SG&A expense | $547,984 | $442,508 | $680,415 | $901,130 | $864,061 | $948,376 | $758,666 | $2.02M |
| Operating income | -$2.20M | -$1.36M | -$2.54M | -$2.69M | -$2.83M | -$1.82M | -$1.64M | -$5.84M |
| Interest expense | $27,500 | — | — | $1 | $2 | $0 | $1,946 | $157,468 |
| Net income | -$2.21M | -$1.36M | -$2.28M | -$5.00M | -$2.78M | -$1.05M | -$1.66M | -$6.05M |
| EBITDA | -$2.20M | -$1.36M | -$2.40M | -$2.28M | -$2.81M | -$1.80M | -$1.21M | -$5.29M |
| EPS (basic) | -1.03 | -0.98 | -6.66 | — | -19.05 | -16.78 | -28.55 | — |
| EPS (diluted) | -1.03 | -0.98 | -6.66 | — | -19.05 | -16.78 | -28.55 | — |
| Weighted avg. shares (diluted) | 2.16M | 1.39M | 341,377 | — | 145,996 | 62,424 | 58,078 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.56M | $4.41M | $2.82M | $6.88M | $2.78M | $588,775 | $782,563 | $1.88M |
| Receivables | $50,448 | $21,257 | $132,848 | $48,298 | $120,931 | $372,469 | $581,652 | $1.44M |
| Inventory | — | — | — | — | — | — | — | $45,110 |
| Current assets | $6.34M | $4.48M | $3.48M | $6.95M | $3.60M | $1.17M | $1.53M | $3.59M |
| PP&E, net | $19,798 | $21,011 | $23,134 | $25,543 | $42,666 | $59,789 | $76,460 | $93,563 |
| Total assets | $9.70M | $7.39M | $6.61M | $9.53M | $9.00M | $6.03M | $6.84M | $9.35M |
| Current liabilities | $5.47M | $5.48M | $5.60M | $6.23M | $5.70M | $5.17M | $4.92M | $5.77M |
| Total liabilities | $5.63M | $5.66M | $5.80M | $6.44M | $5.92M | $5.41M | $5.17M | $6.04M |
| Shareholders' equity | $4.07M | $1.74M | $814,038 | $3.09M | $3.07M | $621,973 | $1.67M | $3.31M |
| Shares outstanding | 2.76M | 1.52M | 741,556 | 211,976 | 9.77M | 2.50M | 2.50M | 1.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.70M | -$689,625 | -$3.36M | -$916,923 | -$2.04M | -$192,234 | -$1.10M | -$3.57M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $7,865 |
| Free cash flow | — | — | — | -$916,923 | -$2.04M | — | — | -$3.58M |
| Investing cash flow | -$700,941 | $0 | -$700,000 | $0 | -$1.00M | — | — | -$73,060 |
| Financing cash flow | $4.54M | — | — | $5.01M | $5.23M | — | — | $3.77M |
| Depreciation & amortization | $2,154 | $2,123 | $135,945 | $407,731 | $17,123 | $17,125 | $432,709 | $548,036 |
| Stock-based compensation | $153 | $153 | $1,028 | $1,765 | $1,797 | $1,803 | $15,901 | $10,972 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.